Literature DB >> 11708541

Trends over time in the management of subarachnoid haemorrhage in newcastle: review of 1609 patients.

B Ogungbo1, B A Gregson, A Blackburn, A D Mendelow.   

Abstract

This article reviews trends in the management of subarachnoid haemorrhage (SAH) at the Regional Neurosurgery Unit in Newcastle over 9 years. This is a comprehensive analysis of prospectively collected data on patients with SAH. We review the changes in clinical therapy and outcome with regards to conservative (non-surgical), surgical and endovascular therapy. Since 1990, the demographic and management/outcome details of patients with SAH have been recorded systematically. This study involves patients admitted over the 9 years, from January 1990 to December 1998. The data were computerized using Microsoft Access (Microsoft Inc. USA), and analysed using SPSS statistical package. A total of 1609 had aneurysmal SAH confirmed with CT, lumbar puncture and/or angiography. Sixty-seven per cent (1,073 patients) were female with a female to male ratio of 2:1. This ratio was maintained from 1990 to date. The mean age has slowly increased from 49 years in 1990 to 55 years of age in 1998, (range 18-91). Overall, 53.9% (from 66.3% in 1990 to 35.3% in 1998) were surgically treated, 8.1% had embolization (range 0.6-18.4%) and 38% (range 28.2-46.4%) were managed without surgical intervention for the aneurysm. The proportion of patients undergoing surgery has decreased since 1994 with improvements in endovascular therapy, participation in the ISAT trial and increased admission of poor grade patients (WFNS grades 4 and 5, from 17% in 1990 to 31% in 1998). The mortality rate has doubled over the years under review (18-32%). The percentage of severely disabled patients has remained constant at about 7% with none in a vegetative state. Only 54% had a favourable outcome in 1998 compared with 78% in 1990. Total morbidity and mortality has increased particularly during the last 3 years. This has been associated with double the number of admissions in grade 5. Favourable outcome occurred in 90% of good grade patients (WFNS 1 and 2) with 6.2% mortality in surgical candidates and 5.5% in patients treated endovascularly. The mortality for poor grade (WFNS 4 and 5) patients was 64%.

Entities:  

Mesh:

Year:  2001        PMID: 11708541     DOI: 10.1080/02688690120082387

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  6 in total

1.  Endovascular treatment of ACom intracranial aneurysms. Report on series of 280 patients.

Authors:  S Finitsis; R Anxionnat; A Lebedinsky; P C Albuquerque; M F Clayton; L Picard; S Bracard
Journal:  Interv Neuroradiol       Date:  2010-03-25       Impact factor: 1.610

2.  Acute endovascular treatment of ruptured aneurysms in poor-grade patients.

Authors:  M Bergui; G B Bradac
Journal:  Neuroradiology       Date:  2003-12-20       Impact factor: 2.804

3.  Trends over time in the management of 2253 patients with cerebral aneurysms: A single practice experience.

Authors:  Troy D Payner; Itay Melamed; Shaheryar Ansari; Thomas J Leipzig; John A Scott; Andrew J Denardo; Terry G Horner; Kathleen Redelman; Aaron A Cohen-Gadol
Journal:  Surg Neurol Int       Date:  2011-08-13

4.  Aneurismal subarachnoid hemorrhage: who remains for surgical treatment in the post-ISAT era?

Authors:  Marta Koźba-Gosztyła; Bogdan Czapiga; Włodzimierz Jarmundowicz
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

5.  Factors affecting outcome in poor grade subarachnoid haemorrhage: An institutional study.

Authors:  Sannepaneni Kranthi; Barada P Sahu; Purohit Aniruddh
Journal:  Asian J Neurosurg       Date:  2016 Oct-Dec

6.  Eleven Year's Single Center Experience of Endovascular Treatment of Anterior Communicating Artery Aneurysms: Focused on Digital Subtraction Angiography Follow-Up Results.

Authors:  Chae Wook Hur; Chang Hwa Choi; Seung Heon Cha; Tae Hong Lee; Hae Woong Jeong; Jae Il Lee
Journal:  J Korean Neurosurg Soc       Date:  2015-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.